https://www.selleckchem.com/pr....oducts/bgj398-nvp-bg
uction regimens in patients with newly diagnosed multiple myeloma to result in a substantial survival benefit.Better adjuvants are needed for vaccines against seasonal influenza. TLR7 agonists are potent activators of innate immune responses and thereby may be promising adjuvants. Among the imidazoquinoline compounds, 1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine (BBIQ) was reported to be a highly active TLR7 agonist but has remained relatively unexplored because of its commercial unavailability. Indeed, in silico molecul
Me gusta
Comentario
Compartir
